136285-65-9

Basic information

• Product Name: 2-[1.1-dimethyl ethyl ethoxy carbonyl]amino-3-nitro benzoic acid ethyl ester
• Synonyms: 2-[[(1,1-Dimethylethoxy)carbonyl]amino]-3-nitrobenzoic acid ethyl ester;Ethyl-2-(tertiary butoxy carbonyl aMino)-3-nitro benzoate;2-[1.1-diMethyl ethyl ethoxy carbonyl]aMino-3-nitro benzoic acid Ethyl Ester ( C3 );Benzoicacid, 2-[[(1, 1-diMethylethoxy)carbonyl]aMino]-3-nitro-, ethyl ester;Ethyl 2-((tert-butoxycarbonyl)amino)-3-nitrobenzoate;Ethyl 2-[(t-butoxycarbonyl)amino]-3-nitrobenzoate;Candesartan ester intermediate C3;Ethyl 2-((((2-methylpentan-2-yl)oxy)carbonyl)amino)-3-nitrobenzoate
• CAS NO: 136285-65-9
• Molecular Formula: C₁₄H₁₈N₂O₆
• Molecular Weight: 338
• Mol File: 136285-65-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 390.832 °C at 760 mmHg
• Flash Point: 190.169 °C
• Appearance: /
• Density: 1.268
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.00±0.70(Predicted)
• CAS DataBase Reference: 2-[1.1-dimethyl ethyl ethoxy carbonyl]amino-3-nitro benzoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[1.1-dimethyl ethyl ethoxy carbonyl]amino-3-nitro benzoic acid ethyl ester(136285-65-9)
• EPA Substance Registry System: 2-[1.1-dimethyl ethyl ethoxy carbonyl]amino-3-nitro benzoic acid ethyl ester(136285-65-9)

Safety Data

• Hazardous Substances Data: 136285-65-9(Hazardous Substances Data)

Usage

General Description

2-[1.1-dimethyl ethyl ethoxy carbonyl]amino-3-nitro benzoic acid ethyl ester is a complex organic compound. It contains several functional groups including an ether, carbonyl, amino, nitro, and carboxylic acid ethyl ester groups. The compound is a benzoic acid ethyl ester derivative and features a nitro group on the benzene ring, suggesting possible reactivity for further chemical transformations. The presence of the 1.1-dimethyl ethyl ethoxy carbonyl package and an amino group also suggests its reactivity and potential use for synthesis in organic chemistry. The exact properties such as physical state, color, solubility or stability of this particular compound would be dependent on the exact context and conditions.

Upstream product

• 124341-05-5 2-Azidocarbonyl-3-nitro-benzoic acid ethyl ester 
• 75-65-0 tert-butyl alcohol 
• 136285-66-0 3-nitro-phthalic acid-1-ethyl ester-2-chloride 
• 603-11-2 3-nitrophthalic acid 
• 16533-45-2 ethyl 2-carboxy-3-nitrobenzoate 

Downstream Products

• 1073117-28-8 (+/-)-1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-[(N-tert-butoxycarbonyl)-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl]biphenyl-4-yl]methyl]amino]-3-nitrobenzoate 
• 1073117-27-7 2-[(N-tert-butoxycarbonyl)-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl]biphenyl-4-yl]methyl]amino]-3-nitrobenzoic acid 
• 145040-37-5 candesartan cilexetil 
• 906474-56-4 ethyl 2-[(N-tert-butoxycarbonyl)-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl]biphenyl-4-yl]methyl]amino]-3-nitrobenzoate 
• 167487-83-4 1H-benzoimidazole-7-carboxylic acid ethyl ester 
• 577957-02-9 ethyl 2-ethoxy-3H-benzimidazole-4-carboxylate 
• 61063-11-4 2-Amino-3-nitrobenzoic acid,ethyl ester 
• 208772-03-6 ethyl 2-(N-tert-butoxycarbonyl-N-methyl)amino-3-nitrobenzoate 

Relevant articles and documents

Synthesis Method for Candesartan Cilexetil Intermediate

A synthesis method for a candesartan cilexetil intermediate represented by formula (II) is provided. The method includes (1) dissolving a compound represented by formula (IV) to an aprotic solvent to obtain a first mixed solution, and dissolving a phase transfer catalyst and an azidation reagent to water to obtain a second mixed solution; (2) dropping the first mixed solution to the second mixed solution for azidation reaction, and after the reaction is ended, standing and layering same to obtain an organic phase containing a compound represented by formula (V); (3) dropping the obtained organic phase containing the compound represented by formula (V) to tertiary butyl alcohol for rearrangement reaction, and after the reaction is ended, concentrating same to obtain a solid or oily material, then adding a crystallizing solvent to the obtained solid or oily material for recrystallization, and separating same to obtain a crystal.

Benzimidazole derivatives and their use

Novel imidazole derivatives of the formula (I): STR1 wherein R1 is an optionally substituted alkyl group, R2 and R3 are independently a group capable of forming an anion or a group which can be changed thereinto, ring A is a benzene ring optionally having, besides the group shown by R2, further substituents, and X shows linkage of phenylene group and phenyl group directly or through a spacer whose atomic length is not more than 2 and a salt thereof, show antagonistic actions to angiotensin II, thus being useful as therapeutics for cardiovascular diseases.